What's new? Log in Free sign up

Clearside Biomedical (CLSD)

Company Profile

clearside biomedical, inc. is a pharmaceuticals company located in 1220 old alpharetta rd., suite 300, alpharetta, ga, united states.

Company profile

Ticker

CLSD

Exchange

Website

clearsidebio.com/

CEO

George Lasezkay

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Material Contracts & Credit Agreements

CLSD stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Quarterly report

14 Aug 23

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Notice of effectiveness

Correspondence with SEC

Letter from SEC

Shelf registration

Entry into a Material Definitive Agreement

Registration of securities for employees

Quarterly report

12 May 23

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

William D. Humphries

Charles A. Deignan

GEORGE M LASEZKAY

Charles A. Deignan

Richard Croarkin

JEFFREY L EDWARDS

William D. Humphries

Financial summary

Financial statements Chart CLSD financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2023

CLSD institutional ownership history Ownership history

22.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	54	53	+1.9%
Opened positions	8	10	-20.0%
Closed positions	7	11	-36.4%
Increased positions	9	8	+12.5%
Reduced positions	13	14	-7.1%

13F shares	Current	Prev Q	Change
Total value	8.89 bn	8.24 bn	+7.8%
Total shares	13.89 mm	14.16 mm	-1.9%
Total puts	83.60 k	75.10 k	+11.3%
Total calls	64.30 k	79.70 k	-19.3%
Total put/call ratio	1.3	0.9	+38.0%

Largest owners	Shares	Value	Change
Hatteras Venture Advisors III	3.06 mm	$3.70 mm	0.0%
Carmignac Gestion	2.40 mm	$2.69 bn	0.0%
Whitmore Bradford T	2.36 mm	$0.00	0.0%
Vanguard	2.17 mm	$2.43 bn	0.0%
BLK Blackrock	813.31 k	$910.91 mm	+1.9%
Geode Capital Management	499.21 k	$559.11 mm	-5.8%
Renaissance Technologies	336.69 k	$377.00 k	-26.7%
Bridgeway Capital Management	279.60 k	$313.15 mm	-4.1%
STT State Street	193.36 k	$216.57 mm	0.0%
First Manhattan	175.00 k	$196.00 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Renaissance Technologies	336.69 k	-122.70 k	-26.7%
MS Morgan Stanley	172.80 k	+121.16 k	+234.6%
Brown Wealth Management	110.00 k	+110.00 k	NEW
Acadian Asset Management	34.17 k	-103.06 k	-75.1%
Janney Montgomery Scott	0.00	-100.00 k	EXIT
LNC Lincoln National	0.00	-92.30 k	EXIT
Assenagon Asset Management	71.78 k	-79.86 k	-52.7%
Citadel Advisors	17.36 k	-50.15 k	-74.3%
SF Stifel Financial	60.54 k	+47.81 k	+375.6%
Connor, Clark & Lunn Investment Management	15.56 k	-38.23 k	-71.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CLSD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
25 Sep 23	Thorp Clay	Common Stock	Buy	Acquire P	No	No	0.86	10,000	8.60 k	40,522
22 Sep 23	William D. Humphries	Common Stock	Option exercise	Acquire M	No	No	0.4	22,727	9.09 k	51,040
22 Sep 23	William D. Humphries	Stock Option Common Stock	Option exercise	Dispose M	No	No	0.4	22,727	9.09 k	0
18 Sep 23	Deignan Charles A.	Employee Stock Option Common Stock	Grant	Acquire A	No	No	0.849	100,000	84.90 k	100,000
18 Sep 23	Lasezkay George M	Employee Stock Option Common Stock	Grant	Acquire A	No	No	0.849	200,000	169.80 k	200,000
13 Sep 23	Deignan Charles A.	Common Stock	Option exercise	Acquire M	No	No	0.4	34,090	13.64 k	397,562
13 Sep 23	Deignan Charles A.	Employee Stock Option Common Stock	Option exercise	Dispose M	No	No	0.4	34,090	13.64 k	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Clearside Biomedical Granted U.S. Patent #11752101: Ocular injector and methods for accessing suprachoroidal space of the eye

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11752101

Stocks That Hit 52-Week Lows On Friday

Friday's session saw 225 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 179 companies reached new 52-week lows.

JMP Securities Reiterates Market Outperform on Clearside Biomedical, Maintains $5 Price Target

HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target

Press releases

From Benzinga Pro

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS

Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

ALPHARETTA, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical's Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.